Dirk E. Smith, Bainbridge Island, WA (US); Ian Foltz, Burnaby (CA); Chadwick T. King, North Vancouver (CA); Ai Ching Lim, Mercer Island, WA (US); Rutilio Clark, Bainbridge Island, WA (US); Michael R. Comeau, Bainbridge, WA (US); Randal R. Ketchem, Snohomish, WA (US); Donghui Shi, Thousand Oaks, CA (US); Xiaoshan Min, Burlingame, CA (US); and Zhulun Wang, Palo Alto, CA (US)
Assigned to Amgen Inc., Thousand Oaks, CA (US)
Filed by Amgen Inc., Thousand Oaks, CA (US)
Filed on Jun. 4, 2021, as Appl. No. 17/339,301.
Application 17/339,301 is a division of application No. 16/242,278, filed on Jan. 8, 2019, granted, now 11,059,895.
Application 16/242,278 is a division of application No. 15/601,868, filed on May 22, 2017, granted, now 10,227,414, issued on Mar. 12, 2019.
Application 15/601,868 is a division of application No. 15/178,652, filed on Jun. 10, 2016, granted, now 9,982,054, issued on May 29, 2018.
Application 15/178,652 is a division of application No. 13/897,096, filed on May 17, 2013, granted, now 9,382,318, issued on Jul. 5, 2016.
Claims priority of provisional application 61/792,619, filed on Mar. 15, 2013.
Claims priority of provisional application 61/649,147, filed on May 18, 2012.
Prior Publication US 2022/0119537 A1, Apr. 21, 2022
1. A method of treating inflammation in a patient with an autoimmune or inflammatory disorder, comprising administering to the patient a therapeutically effective amount of an antibody that binds ST2, wherein the antibody comprises a light chain variable domain that comprises an LCDR1 sequence as set forth in SEQ ID NO:107; an LCDR2 sequence as set forth in SEQ ID NO:118; and an LCDR3 sequence as set forth in SEQ ID NO:129; and a heavy chain variable domain that comprises an HCDR1 sequence as set forth in SEQ ID NO:41; an HCDR2 sequence as set forth in SEQ ID NO:52; and an HCDR3 sequence as set forth in SEQ ID NO:63; wherein the heavy chain variable domain comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 30 and the light chain variable domain comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 96.